Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3309 - Prognostic role of changes in neutrophil-to-lymphocyte ratio, tumor-infiltrating lymphocyte with programmed death ligand-1 in triple-negative breast cancer

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Immunology

Tumour Site

Breast Cancer

Presenters

Eun Kyo Joung

Citation

Annals of Oncology (2018) 29 (suppl_8): viii87-viii89. 10.1093/annonc/mdy271

Authors

E.K. Joung1, J.E. Lee2

Author affiliations

  • 1 Medical Oncology, Incheon St. Mary's hospital, The Catholic University of Korea, KS006 - Incheon/KR
  • 2 Medical Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, 137-701 - Seoul/KR
More

Resources

Abstract 3309

Background

Neutrophil-to-lymphocyte ratio (NLR), tumor-infiltrating lymphocyte (TIL) and programmed death-ligand 1 (PD-L1) expression is known to be associated with immunogenicity and prognosis of breast cancer. We analyzed baseline NLR and its clinical association in triple-negative breast cancer (TNBC). The changes of NLR, TIL and PD-L1 during neoadjuvant chemotherapy (NAC) and their association to recurrence was analyzed.

Methods

Between Jan 2008 to Dec 2015, 358 TNBC patients were analyzed. NLR was based on initial complete blood count (CBC). Fifty paired NLR (initial diagnosis, after completion of NAC) and 34 paired tissues (initial diagnosis, surgical specimen) were collected. The changes of TIL, CD4, CD8, forkhead box P3 (FOXP3) and PD-L1 expression were assessed with immunohistochemical stain. The relationship of prior markers and tumor recurrence was analyzed.

Results

Low NLR (NLR≤3.16) was associated to superior survival [overall survival; 41.83 vs. 36.5 months, P = 0.002; disease-free survival (DFS) 37.85 vs. 32.14 months, P = 0.032]. After NAC, patients with radical NLR changes (NLR change < -30% or > 100%) showed inferior DFS (38.37 vs. 22.37 months, P = 0.015). Same or increased TIL after NAC showed trends for superior DFS (80.0 vs. 46.0 months, P = 0.366). Positive PD-L1 (≥1%) in tumor cells at baseline was associated to superior DFS (97.45 vs. 33.02 months, P = 0.031), and positive tumor PD-L1 at post-NAC tissues showed trends for superior DFS (86.43 vs. 38.76 months, P = 0.056).

Conclusions

In TNBC patients, low NLR might be associated with superior survival. Modest changes of NLR or increased TIL after NAC may reflect good prognosis. Positive tumor PD-L1 was associated with superior DFS in our study.

Clinical trial identification

Legal entity responsible for the study

Seoul St. Mary's Hospital, Incheon St. Mary's Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.